clinical trial · NCT06297213
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's SyndromeSjögrenSjögren Syndrome, UnspecifiedR-2487
brief summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Sjogren's Syndrome. Patients will take an oral dosage of probiotic (R-2487) and physicians will assess and measure their Sjogren's Syndrome. Blood and fecal evaluations of inflammation and assessment of probiotic (R-2487) on fecal level will also be measured.
started
Nov 1, 2026
primary completion
Aug 30, 2029
completion
Nov 30, 2029
last updated
Nov 6, 2026
official title
A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Sjogren's Syndrome (SjD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol